$23.43
0.090.39%
Ult. Agg.: Oct 26, 9:30 AM
Tango Therapeutics (TNGX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.32 | $-0.32 | $-0.32 | $-0.04 |
| Actual | $-0.37 | $-0.32 | $-0.29 | $0.14 |
| Surprise | -15.6% | 0.00% | +9.38% | +450.0% |
| Revenue | ||||
| Estimate | $1.6M | $578090 | $500400 | $42.2M |
| Actual | $0 | $0 | $0 | $53.8M |
| Surprise | -100.0% | -100.0% | -100.0% | +27.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.35 | $-0.37 | $-0.38 | $-0.40 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.37 | $-0.32 | -15.6 % |
| Q1 | May 13, 2026 | $-0.32 | $-0.32 | 0.00 % |
| Q4 | Mar 5, 2026 | $-0.29 | $-0.32 | 9.38 % |
| Q3 | Nov 4, 2025 | $0.14 | $-0.04 | 450.0 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $0 | $1.56M | -100.0 % |
| Q1 | May 13, 2026 | $0 | $578.09K | -100.0 % |
| Q4 | Mar 5, 2026 | $0 | $500.40K | -100.0 % |
| Q3 | Nov 4, 2025 | $53.81M | $42.22M | 27.5 % |